Drugs / BG-75202
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07619287 | Jun 2026 → Sep 2028 expected | myeloid neoplasm | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT07222267 | Dec 2025 → Sep 2029 expected | breast cancer | BeOne Medicines | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BG-75202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07222267 ↗ |
| Action | Inhibit | “BG-75202 (KAT6A/B inhibitor)” NCT07222267 ↗ |
| Route | Oral | “Administered orally.” NCT07222267 ↗ |
| Target | KAT6A | “BG-75202 (KAT6A/B inhibitor)” NCT07222267 ↗ |